Logo

American Heart Association

  47
  1


Final ID: Mo022

Doxorubicin induces cardiomyopathy through Wnt5a-mediated induction of senescence

Abstract Body: Doxorubicin (DOX) is a chemotherapeutic agent used to treat cancer, but its clinical use is restricted due to cardiotoxicity. Senescence is defined by resistance to apoptosis and a senescence-associated secretory phenotype (SASP). Elimination of senescent cells can improve cardiac dysfunction, suggesting that senescent cardiomyocytes (CMs) contribute to impaired heart function. Although DOX induces senescence in CMs, little is known about the mechanisms mediating DOX-induced senescence and cardiomyopathy. Wnt5a, a non-canonical Wnt ligand, is an important player in cardiac diseases and is upregulated in induced pluripotent stem cell (iPSC)-derived CMs from patients with heart failure induced by DOX chemotherapy. However, the role of Wnt5a in mediating DOX-induced cardiomyopathy remains elusive. Wnt5a protein expression was increased (4.4-fold, p<0.001) in mouse hearts with DOX-induced cardiomyopathy. Upregulation of Wnt5a following DOX treatment was also observed in neonatal rat CMs (NRCMs), and the degree of upregulation was more prominent in CMs (2.1-fold) than in non-CMs (1.1-fold). In NRCMs, Wnt5a induced senescent phenotypes, including increases in the p16 protein level, the number of γH2AX foci per cell and SA-β-gal activity. Wnt5a knockdown reduced DOX-induced increases in the p16 protein level in NRCMs, suggesting that Wnt5a mediates DOX-induced CM senescence. To assess the role of endogenous CM Wnt5a in mediating DOX-induced cardiomyopathy, we generated Myh6-cre Wnt5afl/fl (Wnt5acKO) mice, in which Wnt5a is knocked out in a CM-specific manner. DOX-treated Wnt5acKO mice showed little difference in ejection fraction (EF) compared to PBS-treated Wnt5acKO mice (56.64 ± 6.17% and 57.60 ± 5.23%), while DOX-treated Wnt5afl/fl mice showed a significant decrease in EF (34.63 ± 3.65%, p<0.0001). These results suggest that Wnt5a deletion in CMs impedes the progression of DOX-induced cardiac dysfunction, positioning Wnt5a as a novel therapeutic target for the prevention of DOX-induced cardiomyopathy.
  • Sung, Eun-ah  ( RUTGERS NJMS , Newark , New Jersey , United States )
  • Sadoshima, Junichi  ( RUTGERS NJMS , Newark , New Jersey , United States )
  • Author Disclosures:
    Eun-Ah Sung: DO NOT have relevant financial relationships | Junichi Sadoshima: DO NOT have relevant financial relationships
Meeting Info:

Basic Cardiovascular Sciences

2024

Chicago, Illinois

Session Info:

Poster Session and Reception I

Monday, 07/22/2024 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
A New Small-Molecule ErbB4 Agonist Attenuates Adverse Ventricular Remodeling After Myocardial Infarction In a Sex-Specific Manner

Goovaerts Bo, Civati Celine, Feyen Eline, De Keulenaer Gilles, Segers Vincent

Association Between Arthritis and Heart Failure Among People with Hypertension in United States

Kookanok Chutawat, Lertsakulbunlue Sethapong, Wanichwecharungruang Nisha, Rochanaroon Voramol, Rodsom Kamonluk, Tantisattamo Ekamol, Poochanasri Methavee, Kulthamrongsri Narathorn, Kanthajan Tatchaya, Bhuriveth Varathpavee, Wareesawetsuwan Nicha, Sodsri Tulaton, Sripusanapan Adivitch, Siramongkholkarn Smuch

More abstracts from these authors:
Sirt1 inhibits the Sub1-induced RNA polymerase II recruitment to metabolic gene promoters during pressure overload

Oka Shinichi, Zhai Peiyong, Sadoshima Junichi

Regulation of Ferroptosis by Wnt5a in the Heart: Implication in Cardio-Oncology

Fefelova Nadezhda, Sung Eun-ah, Pamarthi Sri Harika, Piamsiri Chanon, Gwathmey Judith, Sadoshima Junichi, Xie Lai-hua

You have to be authorized to contact abstract author. Please, Login
Not Available